Physician profile
Stephen Parker Lang
NPI 1831270206
$1,801.81
in general payments reported to CMS, 2019-2025
31 companies · $160 in 2025
The $160 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2021: $325 · 2022: $29.43 · 2023: $253 · 2024: $157 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.45 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $277.04 | 2019-2024 | Wegovy |
| Parapro, LLC | $200.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $174.65 | 2019-2021 | |
| Glaxosmithkline, LLC. | $125.00 | 2023 | Shingrix |
| Axsome Therapeutics, INC. | $124.73 | 2025 | Symbravo |
| Medtronic, INC. | $100.51 | 2024 | Signia |
| Amarin Pharma, INC. | $71.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $64.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.19 | 2019 | |
| Pfizer INC. | $55.45 | 2019-2022 | |
| Lilly USA, LLC | $54.79 | 2019 | |
| Amgen INC. | $53.60 | 2019 | |
| Janssen Pharmaceuticals, INC | $46.17 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $43.98 | 2019 | |
| Abbott Laboratories | $41.28 | 2024 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $35.53 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $32.64 | 2019 | |
| Allergan, INC. | $31.59 | 2019 | |
| Shire North American Group INC | $30.12 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.72 | 2019 | |
| Aytu Biopharma, INC. | $18.96 | 2019 | |
| Abbvie INC. | $14.96 | 2019 | |
| Dynavax Technologies Corporation | $14.79 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.66 | 2023 | Xifaxan |
| Tactile Systems Technology INC | $14.20 | 2019 | |
| Merck Sharp & Dohme LLC | $12.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.58 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.21 | 2019 | |
| Mml US, INC. | $4.25 | 2023 | Reactiv8 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.